<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2022.872652</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Trained Immunity Enhances Human Monocyte Function in Aging and Sepsis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gill</surname><given-names>P. Spencer</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/952495"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ozment</surname><given-names>Tammy R.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lewis</surname><given-names>Nicole H.</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sherwood</surname><given-names>Edward R.</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/32365"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Williams</surname><given-names>David L.</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/453522"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Surgery, James H. Quillen College of Medicine, East Tennessee State University</institution>, <addr-line>Johnson City, TN</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Center for Inflammation, Infectious Disease, and Immunity, Quillen College of Medicine, East Tennessee State University</institution>, <addr-line>Johnson City, TN</addr-line>, <country>United States</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Medical Education, Quillen College of Medicine, East Tennessee State University</institution>, <addr-line>Johnson City, TN</addr-line>, <country>United States</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center</institution>, <addr-line>Nashville, TN</addr-line>, <country>United States</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Anesthesiology, Vanderbilt University Medical Center</institution>, <addr-line>Nashville, TN</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Liwu Li, Virginia Tech, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Paola Italiani, National Research Council (CNR), Italy; Jan Fric, International Clinical Research Center (FNUSA-ICRC), Czechia</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: David L. Williams, <email xlink:href="mailto:williamd@etsu.edu">williamd@etsu.edu</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>05</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>872652</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Gill, Ozment, Lewis, Sherwood and Williams</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Gill, Ozment, Lewis, Sherwood and Williams</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Aging plays a critical role in the incidence and severity of infection, with age emerging as an independent predictor of mortality in sepsis. Trained immunity reprograms immunocytes to respond more rapidly and effectively to pathogens and serves as a potential approach to improve immune function in aging and/or sepsis. However, there is very little data on trained immunity in the aging immune system or in the presence of sepsis. We examined the impact of &#x3b2;-glucan induced innate immune training on monocytes from aging healthy humans (&gt;60 years old) as well as sepsis patients. We observed increased metabolic capacity, upregulated cytokine secretion, increased H3K27 acetylation, and upregulation of crucial intracellular signaling pathways in trained monocytes from healthy aging subjects. The response to trained immunity in healthy aging monocytes was equivalent to the response of monocytes from younger, <italic>i.e.</italic>, 18 &#x2013; 59 years, individuals. Additionally, we found that trained immunity induced a unique expression pattern of cell surface markers in monocytes that was consistent across age groups. Trained monocytes from sepsis patients also displayed enhanced metabolic capacity and increased cytokine production. These results indicate that immune training can be induced in aging monocytes as well as monocytes from critically ill sepsis patients.</p>
</abstract>
<kwd-group>
<kwd>trained immunity</kwd>
<kwd>aging</kwd>
<kwd>immunosenescence</kwd>
<kwd>innate immunity</kwd>
<kwd>monocytes</kwd>
</kwd-group>    <contract-num rid="cn001">R01GM122934, RO1AI151210, R01GM119197, RO1GM083016, C0RR036551</contract-num>
<contract-sponsor id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content>
</contract-sponsor>
<counts>
<fig-count count="7"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="44"/>
<page-count count="11"/>
<word-count count="5326"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>It has been estimated that over the next thirty years the number of individuals &gt;60 years of age will more than double, increasing by over a billion; and the number of individuals over age 80 may increase by as much as 300 million (<xref ref-type="bibr" rid="B1">1</xref>). This dramatic increase in the number of older individuals will result in a significant increase in age related diseases. As humans age, our immune system becomes progressively weaker through a process called immune senescence (<xref ref-type="bibr" rid="B1">1</xref>). This age-related decrease in immune function increases susceptibility to infection and sepsis (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>Sepsis is the leading cause of death in non-cardiac intensive care units (ICU) and accounts for 40% of ICU expenditures (<xref ref-type="bibr" rid="B5">5</xref>). Patients that survive sepsis have long-term physical and cognitive disabilities and are frequently re-admitted to the hospital with recurrent infections (<xref ref-type="bibr" rid="B6">6</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Over the past two decades there has been an increased incidence of sepsis (<xref ref-type="bibr" rid="B10">10</xref>) and this trend is likely to continue due to our aging population, increased use of immunosuppressive drugs and invasive procedures, and the emergence of antibiotic resistant opportunistic pathogens (<xref ref-type="bibr" rid="B5">5</xref>). Age has emerged as an independent predictor of morbidity and mortality in sepsis (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>). Indeed, 60% of sepsis cases occur in patients over 65 years of age (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B13">13</xref>). It is generally accepted that age related immune senescence increases susceptibility to infection and sepsis (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B13">13</xref>), which raises the question of whether it is possible to modulate the aging immune system to improve resistance to infection. One possible approach to enhancing immune function during aging is innate immune training (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>There is a substantial literature demonstrating that the innate immune system can be trained to respond more rapidly and effectively to infection (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>). This phenomenon is referred to as &#x201c;trained immunity&#x201d; or &#x201c;innate immune memory&#x201d; (<xref ref-type="bibr" rid="B19">19</xref>). Trained immunity is characterized by metabolic and epigenetic reprogramming in leukocytes in conjunction with enhanced antimicrobial functions (<xref ref-type="bibr" rid="B18">18</xref>). However, there is very limited information available on the effect of trained immunity in aging and/or sepsis. In 2011, Wardhana and colleagues reported that BCG vaccination prevented respiratory infections and improved cytokine production in individuals 60 &#x2013; 75 years of age (<xref ref-type="bibr" rid="B20">20</xref>). Additionally, a 2020 clinical trial found that BCG vaccination increased protection from infection in individuals over 65 years old (<xref ref-type="bibr" rid="B21">21</xref>). While trained immunity increases inflammatory cytokine production upon restiumulation, interestingly Koeken and colleagues found that BCG vaccination reduces systemic inflammation (<xref ref-type="bibr" rid="B22">22</xref>). It is now known that BCG, a potent immune training agent, induces the immune trained phenotype in humans (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B23">23</xref>), thus it is reasonable to speculate that the effect of BCG on respiratory infections in aging subjects may be mediated, in part, by trained immunity. In this study, we examined innate immune training in monocytes isolated from healthy aging subjects and compared and contrasted their response to immune training with monocytes isolated from younger healthy individuals. We also examined innate immune training in monocytes derived from patients diagnosed with sepsis. We found that trained immunity increases metabolism and functionality of monocytes isolated from healthy aging subjects as well as in sepsis patients.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2_1">
<title>Isolation of Human Monocytes From Healthy Subjects</title>
<p>Monocytes have been extensively employed in the study of trained immunity (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Whole blood containing EDTA was purchased from BioIVT (Gray, Tennessee). The blood samples were de&#x2013;identified except for age, gender, and race. BioIVT provided blood that was collected from healthy individuals in 3 age groups, <italic>i.e.</italic> 20&#x2013;30, 31&#x2013;59, &gt;60 years of age. There were 35 individuals in each age group and a total of 105 individuals in the study. The age range for the entire cohort was 20&#x2013;71 years. A detailed description of the subjects is provided in <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>. Monocytes were isolated from whole blood using immunomagnetic negative selection with the EasySep&#x2122; Direct Human Monocyte Isolation Kit (StemCell #19669). Monocyte purity was assessed by flow cytometry. This method yields CD14+ monocyte purity of up to 97.1%.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Age, sex, and race breakdowns for healthy human subjects in each age group.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Age Group</th>
<th valign="top" align="center">Number of Individuals</th>
<th valign="top" align="center">Mean Age (stdev)</th>
<th valign="top" align="center">Female (%)</th>
<th valign="top" align="center">Male(%)</th>
<th valign="top" align="center">Caucasian (%)</th>
<th valign="top" align="center">Black (%)</th>
<th valign="top" align="center">Hispanic (%)</th>
<th valign="top" align="center">Asian(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">20&#x2013;30</td>
<td valign="top" align="center">35</td>
<td valign="top" align="center">25.4 (3.0)</td>
<td valign="top" align="center">16 (45.7%)</td>
<td valign="top" align="center">19 (54.3%)</td>
<td valign="top" align="center">29 (82.9%)</td>
<td valign="top" align="center">2 (5.71)</td>
<td valign="top" align="center">4 (11.4%)</td>
<td valign="top" align="center">0 (0%)</td>
</tr>
<tr>
<td valign="top" align="left">31&#x2013;59</td>
<td valign="top" align="center">35</td>
<td valign="top" align="center">41.8 (8.3)</td>
<td valign="top" align="center">13 (37.1%)</td>
<td valign="top" align="center">22 (62.9%)</td>
<td valign="top" align="center">31 (88.6%)</td>
<td valign="top" align="center">3 (8.6%)</td>
<td valign="top" align="center">1 (2.9%)</td>
<td valign="top" align="center">0 (0%)</td>
</tr>
<tr>
<td valign="top" align="left">60+</td>
<td valign="top" align="center">35</td>
<td valign="top" align="center">65 (3.1)</td>
<td valign="top" align="center">23 (65.7%)</td>
<td valign="top" align="center">12 (34.3%)</td>
<td valign="top" align="center">33 (94.3%)</td>
<td valign="top" align="center">0 (0%)</td>
<td valign="top" align="center">0 (0%)</td>
<td valign="top" align="center">2 (5.7%)</td>
</tr>
<tr>
<td valign="top" align="left">Combined</td>
<td valign="top" align="center">105</td>
<td valign="top" align="center">44.1 (17.2)</td>
<td valign="top" align="center">52 (49.5%)</td>
<td valign="top" align="center">53 (50.5%)</td>
<td valign="top" align="center">93 (88.57%)</td>
<td valign="top" align="center">5 (4.8%)</td>
<td valign="top" align="center">5 (4.8%)</td>
<td valign="top" align="center">2 (1.9%)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_2">
<title>Isolation of Monocytes From Sepsis Patients</title>
<p>Peripheral blood was obtained from sepsis patients at our participating hospital, Johnson City Medical Center, following informed consent (IRB study # 098&#x2013;98s&#x2013;MSHA). All patients met the Sepsis&#x2013;3 criteria (<xref ref-type="bibr" rid="B25">25</xref>). A detailed description of the included sepsis patients is provided in <xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>. Of the 5 patients included in the study, 2 were female and 3 were male. The patients ranged in age from 23&#x2013;78 with the average age being 58.6. The average SOFA score of the cohort was 1.6, and the average Apache II score was 8.4. Peripheral blood was collected in BD Vacutainer<sup>&#xae;</sup> CPT&#x2122; (BD #362760) tubes. Monocytes were isolated from total mononuclear cells using the EasySep&#x2122; Human Monocyte Isolation Kit (StemCell #19359) following manufacturer instructions.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Description of sepsis patients.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Patient</th>
<th valign="top" align="center">Age</th>
<th valign="top" align="center">Race</th>
<th valign="top" align="center">Sex</th>
<th valign="top" align="center">Type of Infection</th>
<th valign="top" align="center">SOFA</th>
<th valign="top" align="center">APACHE</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">1</td>
<td valign="top" align="center">48</td>
<td valign="top" align="left">White</td>
<td valign="top" align="left">Male</td>
<td valign="top" align="left">Staphylococcus aureus</td>
<td valign="top" align="center">0</td>
<td valign="top" align="left">Apache II score: 6 points<break/>(3% postoperative mortality,<break/>8% nonoperative mortality)</td>
</tr>
<tr>
<td valign="top" align="left">2</td>
<td valign="top" align="center">68</td>
<td valign="top" align="left">White</td>
<td valign="top" align="left">Female</td>
<td valign="top" align="left">Staphylococcus aureus</td>
<td valign="top" align="center">2</td>
<td valign="top" align="left">Apache II Score: 9 points<break/>(3% estimated postoperative mortality,<break/>8% estimated nonoperative mortality)</td>
</tr>
<tr>
<td valign="top" align="left">3</td>
<td valign="top" align="center">76</td>
<td valign="top" align="left">White</td>
<td valign="top" align="left">Male</td>
<td valign="top" align="left">Citrobacter species</td>
<td valign="top" align="center">3</td>
<td valign="top" align="left">Apache II Score: 13 points<break/>(7% est postoperative mortality)</td>
</tr>
<tr>
<td valign="top" align="left">4</td>
<td valign="top" align="center">78</td>
<td valign="top" align="left">White</td>
<td valign="top" align="left">Male</td>
<td valign="top" align="left">Enterobacteriaceae,<break/>Klebsiella species</td>
<td valign="top" align="center">3</td>
<td valign="top" align="left">Apache II Score: 8 points</td>
</tr>
<tr>
<td valign="top" align="left">5</td>
<td valign="top" align="center">23</td>
<td valign="top" align="left">White</td>
<td valign="top" align="left">Female</td>
<td valign="top" align="left">Sepsis due to Enterococcus faecalis<break/>(12 days prior to consent)</td>
<td valign="top" align="center">0</td>
<td valign="top" align="left">Apache II Score: 6 points</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2_3">
<title>Immune Training Protocol</title>
<p>Monocytes were adjusted to 5 x 10<sup>5</sup> cells/mL in serum&#x2013;free RPMI 1640 with 1% Antibiotic&#x2013;Antimycotic (Gibco 15240&#x2013;062) and treated with 10 &#x3bc;g/mL &#x3b2;&#x2013;glucan, isolated from <italic>Candida albicans</italic> as previously described (<xref ref-type="bibr" rid="B26">26</xref>). The <italic>C. albicans</italic> &#x3b2;&#x2013;glucan employed in this study was &gt;95% pure. The &#x3b2;&#x2013;glucan was depyrogenated to remove any residual endotoxin, and it was sterile. The lack of endotoxin in the &#x3b2;&#x2013;glucan preparation was established with the HEK&#x2013;Blue LPS Detection kit 2 (Invivogen). Sterility of the &#x3b2;&#x2013;glucan was confirmed by microbiological testing. Isovolumetric PBS was added to monocyte cultures as a control. Monocytes from the same individual were divided between both treatments. Glucan was washed out after 24h (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1A</bold></xref>), and media was replaced with RPMI 1640 with 1% Antibiotic&#x2013;Antimycotic and supplemented with 10% human serum. The media was replenished at day 3. On day 7, the media volume was reduced, and cells were treated with 10 ng/mL LPS (<italic>Escherichia coli</italic> O55:B5, Sigma L6529&#x2013;1MG) or isovolumetric PBS to serve as baseline control for 24 hours. On day 8, the supernatants were harvested for cytokine analysis, and the cells were stained with antibodies for cell surface markers to be analyzed by flow cytometry.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Immune training increases overall metabolic rate of monocytes across all age groups. <bold>(A)</bold> <italic>Ex vivo</italic> trained immunity protocol. <bold>(B)</bold> Baseline and stressed oxygen consumption rate (OCR) 7 days after &#x3b2;&#x2013;glucan or PBS treatment. <bold>(C)</bold> Baseline extracellular acidification rate (ECAR) and stressed ECAR 7 days after &#x3b2;&#x2013;glucan or PBS treatment. Mixed effect model and &#x160;&#xed;d&#xe1;k&#x2019;s multiple comparisons test (*P &#x2264; 0.05, **P &#x2264; 0.01, ***P &#x2264; 0.001, ****P &#x2264; 0.0001) were used to compare <bold>(B, C)</bold> (N=13). ns, not significant.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-872652-g001.tif"/>
</fig>
</sec>
<sec id="s2_4">
<title>Metabolic Assays</title>
<p>Metabolic analysis of isolated monocytes was performed using the Agilent Seahorse XFp Analyzer (Santa Clara, CA). Monocytes were seeded at 1 x 10<sup>5</sup>/well and trained using the protocol defined above. The XFp Cell Energy Phenotype test template was used according to the manufacturer&#x2019;s specifications. Oxygen consumption rate (OCR) was measured to approximate respiration, and extracellular acidification rate (ECAR) was measured to approximate glycolysis. Baseline OCR/ECAR was calculated by averaging the first three measurements prior to oligomycin/FCCP injection. Stressed OCR/ECAR was calculated by averaging the five measurements taken after oligomycin/FCCP injection. Final in well concentrations of oligomycin (Sigma 495455&#x2013;10MG) and FCCP (Sigma C2920&#x2013;10MG) were both 1&#xb5;M.</p>
</sec>
<sec id="s2_5">
<title>Cytokine Measurements</title>
<p>TNF&#x2013;&#x3b1; and IL&#x2013;6 concentrations in conditioned media were analyzed by ELISA (TNA&#x2013;&#x3b1;: BioLegend 430204, IL&#x2013;6: BioLegend 430504). Cell culture supernatants were collected and stored at &#x2013;80&#xb0;C prior to analysis. ELISAs were performed following manufacturer instructions.</p>
</sec>
<sec id="s2_6">
<title>Measurement of Cell Surface Markers by Flow Cytometry</title>
<p>Trained and control cells were harvested, blocked using block buffer (PBS, 5% rabbit serum, 0.5% goat serum albumin, 5 mM EDTA, 0.1% NaN<sub>3</sub>) and stained for flow cytometry using the following mouse anti&#x2013;human antibodies: CD14 FITC, Clone T&#xdc;K4 (Bio&#x2013;Rad MCA1568F), HLA&#x2013;DR PerCP&#x2013;Cy5.5, Clone G56&#x2013;6 (BD Biosciences 560652), CD123 PE, Clone 9F5 (BD Biosciences 555644), CD11b/Mac&#x2013;1 PE&#x2013;Cy7, Clone ICRF44 (BD Biosciences 557743), CD40 APC, Clone 5C3 (BD Biosciences 555591), CD16 Pacific Blue&#x2122;, Clone 3G8 (BD Biosciences 558122). All flow cytometry experiments were performed on a BD LSRFortessa flow cytometer. Cells were gated by forward scatter, side scatter, and CD14 positivity (<xref ref-type="supplementary-material" rid="SM1"><bold>Figure S1B</bold></xref>). Cell gating was adjusted to account for glucan particles that remained from the initial treatment, given that some residual particles remain after multiple wash steps (<xref ref-type="supplementary-material" rid="SM1"><bold>Figure S1A</bold></xref>). Mean fluorescence of isotype controls was subtracted from sample mean fluorescence to normalize between experimental replicates.</p>
</sec>
<sec id="s2_7">
<title>Intracellular Signaling Studies</title>
<p>Trained and control monocytes were adjusted to a density of 5 x 10<sup>6</sup> cells/mL in 12 x75 mm tubes in RPMI 1640. Cells were treated with 10 &#x3bc;g/mL &#x3b2;&#x2013;Glucan or vehicle for 1 or 2 hours at 37&#xb0;C. Cells were fixed using BD Cytofix (BD Biosciences 554655), permeabilized with BD Phosflow Perm Buffer III (BD Biosciences 558050) and stained for 1 hr. with the following antibodies: Alexa Fluor<sup>&#xae;</sup> 488 Mouse anti&#x2013;Akt1, Clone 55/PKBa/Akt (BD Biosciences 560048, Alexa Fluor<sup>&#xae;</sup> 647 Mouse anti&#x2013;Akt (pS473), Clone M89&#x2013;61 (BD Biosciences 560343), PE Mouse Anti&#x2013;mTOR (pS2448), Clone O21&#x2013;404 (BD Biosciences 563489), PerCP/Cyanine5.5 anti&#x2013;ZAP70 Phospho (Tyr319)/Syk Phospho (Tyr352) Antibody, Clone 1503310 (Biolegend 683710). Cells were gated for CD14 positivity on a BD LSRFortessa flow cytometer (<xref ref-type="supplementary-material" rid="SM1"><bold>Figure S2</bold></xref>). Mean fluorescence from fluorescence&#x2013;minus&#x2013;one controls was subtracted from the sample mean fluorescence to normalize between experimental replicates.</p>
</sec>
<sec id="s2_8">
<title>Monocyte Histone Modification in Response to Immune Training</title>
<p>To assess H3K4 methylation, human monocytes were isolated and adjusted to a density of 1x10<sup>6</sup> cells/mL in RPMI 1640, and 2 x10<sup>5</sup> monocytes were plated per well in a 96&#x2013;well plate. Wells were treated with 10 &#x3bc;g/mL &#x3b2;&#x2013;glucan or PBS. Glucan was washed out after 24h on day 1, and media was replaced with RPMI 1640 supplemented with 10% human serum. The media was replenished at day 3. On day 7, cells were assayed for H3K4 methylation using the EpiQuik <italic>In Situ</italic> Histone H3K4 Methylation Assay Kit (EpiGentek P&#x2013;3015&#x2013;096). To assess H3K27 acetylation, 1 x10<sup>6</sup> human monocytes were plated in a 12&#x2013;well plate at 0.5 x 10<sup>5</sup> cell/mL in RPMI 1640 as previously described. Wells were treated with 10 &#x3bc;g/mL &#x3b2;&#x2013;glucan or PBS. Glucan was washed out after 24 hrs. on day 1, and media was replaced with RPMI 1640 supplemented with 10% human serum. The media was replenished at day 3. On day 7, histones were isolated using the EpiQuik Total Histone Extraction Kit (EpiGentek OP&#x2013;0006&#x2013;100) and frozen at &#x2013;80&#xb0;C. H3K27 acetylation was assayed using the EpiQuik Global Acetyl Histone H3K27 Quantification Kit (EpiGentek P&#x2013;4059&#x2013;96).</p>
</sec>
<sec id="s2_9">
<title>Statistical Analysis</title>
<p>All statistical analysis was performed in GraphPad Prism 9 or R. All data are presented as individual values or mean &#xb1; SEM represented by error bars unless otherwise specified. The effect of age and immune training was evaluated using a mixed&#x2013;effect model in which all treatment conditions of a blood sample were paired. &#x160;&#xed;d&#xe1;k&#x2019;s multiple comparisons test was used for all <italic>post hoc</italic> tests. When the assumption of constant variance was not met, a natural log transformation of the data was performed. Simple linear regression was used to determine the effect of age on metabolic rates and cytokine production. Effect of sex on metabolic rates and cytokine production were assessed using a PERMANOVA because the assumption of constant variance was not met. The effect of trained immunity in sepsis was analyzed using a paired T&#x2013;test. When the assumption of constant variance was not met, a Wilcoxon test was performed. An &#x3b1; = 0.05 was used to determine the statistical significance of all measurements.</p>
</sec>
<sec id="s2_10">
<title>Study Approval</title>
<p>This study was approved by the East Tennessee State University Institutional Review board (IRB study # 098&#x2013;98s&#x2013;MSHA). Written informed consent was obtained prior to participation of patients in this study.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Increased Monocyte Metabolism in Response to Immune Training</title>
<p>Cellular metabolism plays a significant role in immune cell function (<xref ref-type="bibr" rid="B27">27</xref>&#x2013;<xref ref-type="bibr" rid="B29">29</xref>). Decreases in respiration and glycolysis have been linked to declining immune systems in aging individuals (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). We found that immune training with &#x3b2;&#x2013;glucan increased baseline and stressed OCR in each age group (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1B</bold></xref>). Immune training also significantly increased baseline and stressed ECAR in all three age groups (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1C</bold></xref>). There was no significant difference in the metabolic status of control and immune trained monocytes across the age groups. We also examined the effect of immune training on monocyte metabolism as a function of gender (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A, B</bold></xref>) or age (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2C, D</bold></xref>). We observed no significant correlation as a function of age or gender (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A&#x2013;F</bold></xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Effect of age and gender on monocyte metabolism in the presence and absence of &#x3b2;&#x2013;glucan induced immune training. <bold>(A)</bold> Scatter plot of baseline and stressed oxygen consumption rate (OCR) 7 days after &#x3b2;&#x2013;glucan or PBS treatment (Female: N=22, Male: N=17). <bold>(B)</bold> Baseline extracellular acidification rate (ECAR) and stressed ECAR 7 days after &#x3b2;&#x2013;glucan or PBS treatment (Female: N=22, Male: N=17). <bold>(C&#x2013;F)</bold> Simple linear regression of baseline and stressed OCR and ECAR. No correlations are significant (N=13). <bold>(A, B)</bold> were analyzed PERMANOVA for sex and training. ns, not significant.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-872652-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>Differential Effect of Monocyte Immune Training on Cytokine Production</title>
<p>Increased cytokine production in response to immune training with &#x3b2;&#x2013;glucan is a hallmark of the immune trained phenotype (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B32">32</xref>). To assess monocyte function, we measured IL&#x2013;6 and TNF&#x2013;&#x3b1; secretion following immune training. We found that immune training with &#x3b2;&#x2013;glucan increased TNF&#x2013;&#x3b1; expression in all three age groups (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3A</bold></xref>). There was no significant effect of gender or age on TNF&#x2013;&#x3b1; expression (<xref ref-type="fig" rid="f3"><bold>Figures&#xa0;3C, E</bold></xref>). There was no effect of immune training on IL&#x2013;6 expression across all age groups. (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>), indicating a differential effect of immune training on cytokine expression. However, IL&#x2013;6 expression positively correlated with age in untrained monocytes (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3F</bold></xref>). While there was a trend toward increased IL&#x2013;6 production as a function of age in trained monocytes (p = 0.0518), it did not reach statistical significance (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3F</bold></xref>). There was no significant effect of gender on IL&#x2013;6 expression (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3D</bold></xref>).</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Immune training stimulated increased monocyte cytokine expression. <bold>(A)</bold> Scatter plot of TNF&#x2013;&#x3b1; expression 7 days after &#x3b2;&#x2013;glucan or PBS treatment, followed by LPS (N=11,12). TNF&#x2013;&#x3b1; expression was below the limit of detection in trained and control monocytes that were not subsequently challenged with LPS. <bold>(B)</bold> IL&#x2013;6 expression (N=10&#x2013;12). IL&#x2013;6 expression was limit of detection at baseline. <bold>(C)</bold> Scatter plot of TNF&#x2013;&#x3b1; expression after LPS stimulation (10ng/mL) 7 days after &#x3b2;&#x2013;glucan or PBS treatment (Female: N=18, Male: N=14). <bold>(D)</bold> IL&#x2013;6 expression after LPS stimulation (Female: N=17, Male: N=14). <bold>(E)</bold> Scatter plot and simple linear regression of TNF&#x2013;&#x3b1; expression by age in control and trained cells. Correlations are not significant (N=35). <bold>(F)</bold> Scatter plot and simple linear regression of IL&#x2013;6 expression in trained and control cells. Control cells: R<sup>2 =</sup> 0.1792, P=0.0158 (N=32). Trained cells: R<sup>2 =</sup> 0.0.1203, P=0.0518 (N=32). A and B measured were analyzed with a mixed effect model and &#x160;&#xed;d&#xe1;k&#x2019;s multiple comparisons test. C and D were analyzed by PERMANOVA for sex and training (**P &#x2264; 0.01, ***P &#x2264; 0.001, ****P &#x2264; 0.0001, ns, not significant).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-872652-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>Differential Effect of Immune Training on Monocyte Histone Methylation and Acetylation</title>
<p>Increased H3K4 methylation and H3K27 acetylation are associated with immune training and improved response to infection (<xref ref-type="bibr" rid="B18">18</xref>). We found that immune training significantly altered monocyte H3K4 methylation (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4A</bold></xref>). However, only H3K4 methylation in the 20&#x2013;30 age group was significantly increased (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4A</bold></xref>). We also observed that immune training had a significant effect on H3K27 acetylation (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4B</bold></xref>). Interestingly, H3K27 acetylation was significantly increased in immune&#x2013;trained cells in the 60+ age group, but not in the younger groups (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4B</bold></xref>). Thus, we observed a differential effect of &#x3b2;&#x2013;glucan induced histone modification in that H3K4 methylation was increased in monocytes derived from healthy young individuals, while H3K27 acetylation was significantly increased in monocytes from aging individuals.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Immune training differentially stimulates monocyte histone modifications. <bold>(A)</bold> H3K4 methylation measured <italic>in situ</italic> 7 days after immune training with &#x3b2;&#x2013;glucan or baseline control (N=5). <bold>(B)</bold> Histone H3K27 methylation 7 days after immune training with &#x3b2;&#x2013;glucan or baseline control (N=6). All measured were analyzed with a mixed effect model and &#x160;&#xed;d&#xe1;k&#x2019;s multiple comparisons test (*P &#x2264; 0.05, **P &#x2264; 0.01, ns, not significant).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-872652-g004.tif"/>
</fig>
</sec>
<sec id="s3_4">
<title>Activation of Intracellular Signaling Pathways in Response to Immune Training</title>
<p>Cheng and colleagues have shown that &#x3b2;&#x2013;glucan induced immune training in monocytes is mediated <italic>via</italic> an Akt/mTOR/HIF1&#x2013;&#x3b1; dependent mechanism (<xref ref-type="bibr" rid="B14">14</xref>). Dectin&#x2013;1 is one of the primary receptors for &#x3b2;&#x2013;glucan (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>) and may be required for &#x3b2;&#x2013;glucan mediated trained immunity (<xref ref-type="bibr" rid="B14">14</xref>). Syk tyrosine kinase is an important downstream mediator of Dectin&#x2013;1 dependent signaling and is critical in Dectin&#x2013;1 mediated immune responses (<xref ref-type="bibr" rid="B35">35</xref>). We examined the effect of immune training, as a function of age, on Syk, Akt and mTor dependent signaling. We found that phosphorylated Syk was increased in monocytes treated for 1 hour with &#x3b2;&#x2013;glucan across all age groups (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref>). However, only trained monocytes from young individuals expressed significantly higher levels of phosphorylated Syk at 2 hrs. stimulation (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref>). We found that AKT phosphorylation was upregulated in monocytes treated for 1 hour with &#x3b2;&#x2013;glucan across all age groups (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5B</bold></xref>). Monocytes from the 20&#x2013;30 and 31&#x2013;59 age groups that were trained with &#x3b2;&#x2013;glucan for 2 hrs. showed significantly higher phosphorylated AKT (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5B</bold></xref>). However, this effect was not observed in the 60+ age group. Phosphorylated mTOR was significantly increased in monocytes treated with &#x3b2;&#x2013;glucan for one or two hours across all age groups (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5C</bold></xref>). Total AKT expression was significantly increased in &#x3b2;&#x2013;glucan trained monocytes at 1 and 2 hrs., although there was no significant difference at 1 hr. in the 31&#x2013;59 group (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5D</bold></xref>). The flow cytometry gating strategy for the intracellular signaling studies is shown in <xref ref-type="supplementary-material" rid="SM1"><bold>Figures S1, S2</bold></xref>.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Immune training activates intracellular signaling pathways in monocytes. <bold>(A)</bold> Scatterplot depicting phosphorylated&#x2013;Syk 1 and 2 hours after &#x3b2;&#x2013;glucan or PBS treatment (N=8&#x2013;12). <bold>(B)</bold> Scatterplot depicting phosphorylated&#x2013;AKT expression (N=9&#x2013;13). <bold>(C)</bold> Scatterplot depicting phosphorylated&#x2013;mTOR (N=9&#x2013;13). <bold>(D)</bold> Scatterplot depicting total AKT expression (N=9&#x2013;13). All results analyzed using a mixed&#x2013;effect model and &#x160;&#xed;d&#xe1;k&#x2019;s multiple comparisons test (*P &#x2264; 0.05, **P &#x2264; 0.01, ***P &#x2264; 0.001, ****P &#x2264; 0.0001, ns, not significant).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-872652-g005.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>Effect of Immune Training on Monocyte Phenotype as a Function of Age</title>
<p>Previous studies have demonstrated that age plays a significant role in the phenotype of CD14+ monocytes (<xref ref-type="bibr" rid="B36">36</xref>&#x2013;<xref ref-type="bibr" rid="B38">38</xref>). In addition, immune training with &#x3b2;&#x2013;glucan has been reported to alter the expression of cell surface markers on monocytes (<xref ref-type="bibr" rid="B32">32</xref>). We measured the expression of cell surface markers in trained and control monocytes in the presence and absence of LPS secondary stimulation. We found that immune&#x2013;trained cells in all age groups showed lower levels of CD16+ cells, indicating a higher relative abundance of intermediate or non&#x2013;classical monocytes (CD14+, CD16+) (<xref ref-type="bibr" rid="B39">39</xref>). Interestingly, this effect was not observed after LPS stimulation (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6A</bold></xref>). CD11b/Mac&#x2013;1 expression was only significantly altered in trained monocytes from the 20 &#x2013; 30 age group and only following LPS stimulation (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6B</bold></xref>). CD123 expression was not altered in immune trained monocytes (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6C</bold></xref>). In contrast, immune training significantly decreased monocyte cell surface HLA&#x2013;DR (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6D</bold></xref>). CD40 was significantly decreased by immune training in monocytes from the 60+ age group (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6E</bold></xref>). In the presence of LPS secondary stimulation, CD40 was decreased in all three age groups (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6E</bold></xref>). When taken together, these data are suggestive of differentiation toward an M2 macrophage phenotype.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Immune training with &#x3b2;&#x2013;glucan alters monocyte phenotype. Isolated human monocytes were trained with &#x3b2;&#x2013;glucan or vehicle control and allowed to rest for 7 days. After 7 days, monocytes were treated with LPS (10ng/mL) or PBS (baseline control) for 24 hours. Cell surface markers were analyzed by flow cytometry. <bold>(A)</bold> Scatterplot depicting the percent of isolated CD14+ monocytes expressing CD16 in LPS&#x2013;stimulated and unstimulated cells. <bold>(B)</bold> Mean fluorescence of CD11b/Mac&#x2013;1. <bold>(C)</bold> Mean fluorescence of cell surface CD123. <bold>(D)</bold> Mean fluorescence of cell surface HLA&#x2013;DR. <bold>(E)</bold> Mean fluorescence of cell surface CD40. All results analyzed using a mixed effect model and &#x160;&#xed;d&#xe1;k&#x2019;s multiple comparisons test (*P &#x2264; 0.05, ***P &#x2264; 0.001, ****P &#x2264; 0.0001) (N=10&#x2013;14). ns, not significant.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-872652-g006.tif"/>
</fig>
</sec>
<sec id="s3_6">
<title>&#x3b2;&#x2013;Glucan Induces the Immune Trained Phenotype in Monocytes Derived From Sepsis Patients</title>
<p>The data above clearly show that monocytes from healthy aging and younger individuals can be trained in response to &#x3b2;&#x2013;glucan. However, there is no data available on the ability of monocytes from septic patients to exhibit the immune trained phenotype. Therefore, we isolated monocytes from patients meeting the broad criteria of Sepsis&#x2013;3. Monocytes isolated from septic patients were trained with &#x3b2;&#x2013;glucan employing the protocol in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1A</bold></xref> and allowed to rest for 7 days. After 7 days, monocytes were assayed for OCR to approximate respiration and ECAR to approximate glycolysis using the Agilent XFp Cell Energy Phenotype Test protocol. Trained septic monocytes had significantly higher baseline and stressed OCR than control septic monocytes (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7A</bold></xref>). Baseline ECAR was increased in trained septic monocytes (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7B</bold></xref>). While stressed ECAR showed an increase, there was no statistically significant effect of immune training on stressed ECAR (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7B</bold></xref>). Additionally, immune trained monocytes from sepsis patients upregulated TNF&#x2013;&#x3b1; (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7C</bold></xref>) and IL&#x2013;6 (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7D</bold></xref>) upon LPS stimulation. These data clearly show that monocytes from septic patients are capable of exhibiting the immune trained phenotype and their functionality is increased, in a fashion similar to healthy aging subjects.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Immune training with &#x3b2;&#x2013;glucan induces metabolic changes and cytokine expression in monocytes from sepsis patients. <bold>(A)</bold> Baseline and stressed OCR 7 days after &#x3b2;&#x2013;glucan or PBS treatment. <bold>(B)</bold> Baseline and stressed ECAR 7 days after &#x3b2;&#x2013;glucan or PBS treatment. Stressed ECAR in trained septic monocytes showed an increased trend versus control monocytes, but did not achieve statistical significance (P=0.0625, N=5). <bold>(C)</bold> TNF&#x2013;&#x3b1; expression 7 days after &#x3b2;&#x2013;glucan or PBS treatment after 24h LPS stimulation. <bold>(D)</bold> IL&#x2013;6 expression. TNF&#x2013;&#x3b1; and IL&#x2013;6 expression were below limit of detection levels in cells that were not treated with LPS 7 days after training or control treatment. All measures, unless otherwise specified, were analyzed using a paired t&#x2013;test (*P &#x2264; 0.05, **P &#x2264; 0.01, ***P &#x2264; 0.001) (N=5). ns, not significant.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-13-872652-g007.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>In the present study, we utilized an <italic>ex vivo</italic> approach to demonstrate that innate immune training can be induced in aging immune cells. We employed &#x3b2;&#x2013;glucan to induce the immune trained phenotype (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). We found that monocytes from healthy subjects &gt;60 years old display the trained immunity phenotype after exposure to &#x3b2;&#x2013;glucan. Immune&#x2013;trained monocytes in aging individuals showed higher metabolic capacities, increased cytokine production, and increased expression of epigenetic markers associated with the trained immunity phenotype (<xref ref-type="bibr" rid="B18">18</xref>). In addition, we also found that monocytes from sepsis patients displayed the immune trained phenotype following &#x3b2;&#x2013;glucan exposure. To the best of our knowledge, this is the first demonstration of innate immune training in human aging and sepsis.</p>
<p>Increased cytokine expression in monocytes following exposure to low levels of LPS is a <italic>ex vivo</italic> hallmark of the trained immune phenotype (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B24">24</xref>). We observed an increase in TNF&#x3b1; expression in response to immune training similar to other reports (<xref ref-type="bibr" rid="B14">14</xref>). However, we did not observe a significant increase in IL&#x2013;6 in immune trained monocytes as a function of age or gender. This indicates a differential effect of &#x3b2;&#x2013;glucan induced trained immunity on human monocyte cytokine expression in our model. This result is in contrast to the data of Cheng and colleagues who reported up regulation of TNF&#x3b1; and IL&#x2013;6 in human monocytes following immune training with the &#x3b2;&#x2013;glucan training reagent (<xref ref-type="bibr" rid="B14">14</xref>).</p>
<p>In addition to characterizing the trained immunity phenotype in &#x3b2;&#x2013;glucan treated monocytes from aging individuals, we also examined the intracellular signaling pathways associated with the trained phenotype in aging monocytes. Previous studies have shown that Dectin&#x2013;1 signaling, Akt and mTOR activation are essential for induction of the immune trained phenotype and increased resistance to infection (<xref ref-type="bibr" rid="B14">14</xref>). In this study, we observed increased Syk phosphorylation after &#x3b2;&#x2013;glucan exposure which is consistent with Dectin&#x2013;1 signaling (<xref ref-type="bibr" rid="B34">34</xref>). We also found up&#x2013;regulation of total AKT, p&#x2013;AKT, and p&#x2013;mTOR, which supports activation of these signaling pathways in monocytes across all age groups. There was no effect of age on the expression levels of these key signaling molecules. When taken together these results indicate that pathways crucial to the induction of trained immunity remain viable in healthy aging monocytes and that these pathways can be modulated by &#x3b2;&#x2013;glucan induced immune training.</p>
<p>Interestingly, immune training led to a relative reduction in CD14<sup>+</sup>/CD16<sup>+</sup> cells. This population of monocytes is known to be expanded in elderly individuals and is thought to represent a less differentiated population of cells (<xref ref-type="bibr" rid="B42">42</xref>). Additionally, we found that immune training decreased expression of the activation markers HLA&#x2013;DR and CD40 regardless of age. Decreased expression of HLA&#x2013;DR and costimulatory molecules is suggestive of differentiation toward an M2 macrophage phenotype (<xref ref-type="bibr" rid="B43">43</xref>). This result is supported by the study of Leonhardt et&#xa0;al., which found that &#x3b2;&#x2013;glucan induced monocyte differentiation towards an M2 phenotype (<xref ref-type="bibr" rid="B43">43</xref>). Furthermore, this may help to explain the upregulation of the anti&#x2013;inflammatory cytokine, IL&#x2013;10, in trained immunity which has been previously described (<xref ref-type="bibr" rid="B41">41</xref>), since IL&#x2013;10 expression is a hallmark of the M2 macrophage. This result suggests that trained macrophages may also play a role in limiting host injury during infection (<xref ref-type="bibr" rid="B43">43</xref>).</p>
<p>It is well established that as humans age our immune systems become progressively weaker (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). This unavoidable process begins during the sixth decade of life when the immune system undergoes age related changes which ultimately progress to immunosenescence (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The impact of immunosenescence is multi&#x2013;faceted and multi&#x2013;factorial (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). It is also well established that aging is associated with the development of a pro&#x2013;inflammatory state, known as &#x201c;inflammaging&#x201d; (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). In this study, we demonstrated that immune training with &#x3b2;&#x2013;glucan induced the trained phenotype across all age groups and there was no substantive difference in ability of aging monocytes to exhibit the immune trained phenotype. This finding may have implications for modulation of innate immune function in aging individuals. We also noted that there was a significant correlation between control (non&#x2013;trained) monocytes derived from healthy aging individuals and increased IL&#x2013;6 production, which is consistent with age related inflammaging (<xref ref-type="bibr" rid="B27">27</xref>). In contrast, we found that immune training diminished monocyte IL&#x2013;6 production as a function of age. Thus, our data indicate that &#x3b2;&#x2013;glucan induced immune training did not exacerbate IL&#x2013;6 production in aging monocytes. Additional studies will be required to further elucidate the impact of immune training on inflammaging.</p>
<p>There are some limitations to our study. We employed an <italic>ex vivo</italic> monocyte model. Thus, we cannot know how immune training would affect other immunocytes or other cells in aging and/or septic individuals. We also did not address how long trained immunity in monocytes may last in this study. This is due to the fact that our <italic>ex vivo</italic> model is not suited for longer&#x2013;term studies as monocyte viability decreases after 7 days in culture (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B44">44</xref>). It is also possible that the monocytes isolated in our study differentiated into macrophage&#x2013;like cells during the seven day incubation. However, we refer to trained and control cells as monocytes due to convention established in previous papers within the trained immunity field (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B32">32</xref>).</p>
<p>In conclusion, this study confirms that innate immune training can be induced in aging healthy individuals as well as critically ill sepsis patients. We found that innate immune training can be induced regardless of age and there was no substantive difference in the immune trained phenotype as a function of age. We employed &#x3b2;&#x2013;glucan as our immune training stimulus. The ability of glucan to induce the trained phenotype suggests that it may be possible to pharmacologically induce the immune trained phenotype in aging human immunocytes. When taken together, our data suggests that innate immune training may be a viable prophylactic and/or therapeutic approach to preventing and/or treating infection in vulnerable populations, such as the elderly.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by East Tennessee State Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>PG, TO, ES, and DW conceived, planned and designed the experiments. PG and TO carried out the experiments and acquired the data. PG and NL performed the statistical analyses. PG, TO, NL, ES and DW contributed to data analysis and interpretation of the results. PG took the lead in writing the manuscript. All authors provided critical feedback and helped to shape the final manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported, in part, by the National Institutes of Health (NIH) Grants R01GM122934 to TO, RO1 AI151210 to consistency, R01GM119197 to ES and DW, RO1GM083016 to DW and C0RR036551 to ETSU. The funding agency had no role in the study design, data collection, data interpretation or preparation of this manuscript. Content of this manuscript has previously appeared online in P. Spencer Gill&#x2019;s doctoral dissertation &#x201c;Trained Immunity Enhances the Immune Response and Maintains Microbiome Diversity in Aging and Sepsis.&#x201d;</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2022.872652/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2022.872652/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.pdf" id="SM1" mimetype="application/pdf"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadighi Akha</surname> <given-names>AA</given-names>
</name>
</person-group>. <article-title>Aging and the Immune System: An Overview</article-title>. <source>J Immunol Methods</source> (<year>2018</year>) <volume>463</volume>:<page-range>21&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jim.2018.08.005</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jackaman</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tomay</surname> <given-names>F</given-names>
</name>
<name>
<surname>Duong</surname> <given-names>L</given-names>
</name>
<name>
<surname>Abdol Razak</surname> <given-names>NB</given-names>
</name>
<name>
<surname>Pixley</surname> <given-names>FJ</given-names>
</name>
<name>
<surname>Metharom</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Aging and Cancer: The Role of Macrophages and Neutrophils</article-title>. <source>Ageing Res Rev</source> (<year>2017</year>) <volume>36</volume>:<page-range>105&#x2013;16</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.arr.2017.03.008</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunha</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Perazzio</surname> <given-names>SF</given-names>
</name>
<name>
<surname>Azzi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cravedi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Riella</surname> <given-names>LV</given-names>
</name>
</person-group>. <article-title>Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID&#x2013;19 Immune Response</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>1748</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.01748</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ventura</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Casciaro</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gangemi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Buquicchio</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Immunosenescence in Aging: Between Immune Cells Depletion and Cytokines Up&#x2013;Regulation</article-title>. <source>Clin Mol Allergy</source> (<year>2017</year>) <volume>15</volume>:<fpage>21</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12948-017-0077-0</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantovani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cassatella</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Costantini</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jaillon</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Neutrophils in the Activation and Regulation of Innate and Adaptive Immunity</article-title>. <source>Nat Rev Immunol</source> (<year>2011</year>) <volume>11</volume>:<page-range>519&#x2013;31</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri3024</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname> <given-names>CJ</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>de Assuncao</surname> <given-names>MSC</given-names>
</name>
</person-group>. <article-title>Myocardial Dysfunction in Sepsis: A Large, Unsolved Puzzle</article-title>. <source>Crit Care Res Pract</source> (<year>2012</year>) <volume>2012</volume>:<fpage>1</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2012/896430</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Derhovanessian</surname> <given-names>A</given-names>
</name>
<name>
<surname>De Cruz</surname> <given-names>S</given-names>
</name>
<name>
<surname>Belperio</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Hoo</surname> <given-names>GS</given-names>
</name>
</person-group>. <article-title>Subsequent Infections in Survivors of Sepsis: Epidemiology and Outcomes</article-title>. <source>J Intensive Care Med</source> (<year>2014</year>) <volume>29</volume>(<issue>2</issue>):<fpage>87</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0885066612467162</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delano</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>PA</given-names>
</name>
</person-group>. <article-title>Sepsis&#x2013;Induced Immune Dysfunction: Can Immune Therapies Reduce Mortality</article-title>. <source>J Clin Invest</source> (<year>2016</year>) <volume>126</volume>(<issue>1</issue>):<fpage>23</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1172/JCI82224</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delano</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>PA</given-names>
</name>
</person-group>. <article-title>The Immune System's Role in Sepsis Progression, Resolution, and Long&#x2013;Term Outcome</article-title>. <source>Immunol Rev</source> (<year>2016</year>) <volume>274</volume>:<page-range>330&#x2013;53</page-range>. doi: <pub-id pub-id-type="doi">10.1111/imr.12499</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayr</surname> <given-names>FB</given-names>
</name>
<name>
<surname>Yende</surname> <given-names>S</given-names>
</name>
<name>
<surname>Angus</surname> <given-names>DC</given-names>
</name>
</person-group>. <article-title>Epidemiology of Severe Sepsis</article-title>. <source>Virulence</source> (<year>2014</year>) <volume>5</volume>(<issue>1</issue>):<fpage>4</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.4161/viru.27372</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kline</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Bowdish</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Infection in an Aging Population</article-title>. <source>Curr Opin Microbiol</source> (<year>2016</year>) <volume>29</volume>:<page-range>63&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.mib.2015.11.003</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Vught</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Klein Klouwenberg</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Spitoni</surname> <given-names>C</given-names>
</name>
<name>
<surname>Scicluna</surname> <given-names>BP</given-names>
</name>
<name>
<surname>Wiewel</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Horn</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis</article-title>. <source>JAMA</source> (<year>2016</year>) <volume>15</volume>(<issue>14</issue>):<page-range>1469&#x2013;79</page-range>. doi: <pub-id pub-id-type="doi">10.1001/jama.2016.2691</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gs</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mannino</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Moss</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The Effect of Age on the Development and Outcome of Adult Sepsis</article-title>. <source>Crit Care Med</source> (<year>2006</year>) <volume>34</volume>(<issue>1</issue>):<fpage>15</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1097/01.ccm.0000194535.82812.ba</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Quintin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cramer</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Shepardson</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Saeed</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>mTOR&#x2013; and HIF&#x2013;1a&#x2013;Mediated Aerobic Glyolysis as Metabolic Basis for Trained Immunity</article-title>. <source>Science</source> (<year>2014</year>) <volume>345</volume>(<issue>6204</issue>):<fpage>1579</fpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1250684</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Divangahi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Aaby</surname> <given-names>P</given-names>
</name>
<name>
<surname>Khader</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Barreiro</surname> <given-names>LB</given-names>
</name>
<name>
<surname>Bekkering</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chavakis</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Trained Immunity, Tolerance, Priming and Differentiation: Distinct Immunological Processes</article-title>. <source>Nat Immunol</source> (<year>2020</year>) <volume>22</volume>:<fpage>2</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41590-020-00845-6</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kleinnijenhuis</surname> <given-names>J</given-names>
</name>
<name>
<surname>Quintin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Preijers</surname> <given-names>F</given-names>
</name>
<name>
<surname>Joosten</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Ifrim</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Saeed</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Bacille Calmette&#x2013;Guerin Induces NOD2&#x2013;Dependent Nonspecific Protection From Reinfection <italic>via</italic> Epigenetic Reprogramming of Monocytes</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2012</year>) <volume>109</volume>(<issue>43</issue>):<page-range>17537&#x2013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1202870109</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moorlag</surname> <given-names>SJCFM</given-names>
</name>
<name>
<surname>Rodriguez&#x2013;Rosales</surname> <given-names>YA</given-names>
</name>
<name>
<surname>Gillard</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fanucchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Theunissen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Novakovic</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>BCG Vaccination Induces Long&#x2013;Term Functional Reprogramming of Human Neutrophils</article-title>. <source>Cell Rep</source> (<year>2020</year>) <volume>33</volume>(<issue>7</issue>):<fpage>108387</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2020.108387</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saeed</surname> <given-names>S</given-names>
</name>
<name>
<surname>Quintin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kerstens</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Aghajanirefah</surname> <given-names>A</given-names>
</name>
<name>
<surname>Matarese</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Epigenetic Programming of Monocyte&#x2013;to&#x2013;Macrophage Differentiation and Trained Innate Immunity</article-title>. <source>Science</source> (<year>2014</year>) <volume>345</volume>(<issue>6204</issue>):<fpage>1251086</fpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1251086</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Netea</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Dominguez&#x2013;Andres</surname> <given-names>J</given-names>
</name>
<name>
<surname>Barreiro</surname> <given-names>LB</given-names>
</name>
<name>
<surname>Chavakis</surname> <given-names>T</given-names>
</name>
<name>
<surname>Divangahi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fuchs</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Defining Trained Immunity and its Role in Health and Disease</article-title>. <source>Nat Rev Immunol</source> (<year>2020</year>) <volume>20</volume>(<issue>6</issue>):<page-range>375&#x2013;88</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wardhana</surname></name>
<name>
<surname>Datau</surname> <given-names>E</given-names>
</name>
<name>
<surname>Sultana</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mandang</surname> <given-names>V</given-names>
</name>
<name>
<surname>Jim</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>The Efficacy of Bacillus Calmette&#x2013;Guerin Vaccinations for the Prevention of Acute Upper Respiratory Tract Infection in the Elderly</article-title>. <source>Acta Med Indonesiana</source> (<year>2011</year>) <volume>43</volume>(<issue>3</issue>):<page-range>185&#x2013;90</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.08.018</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giamarellos&#x2013;Bourboulis</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Tsilika</surname> <given-names>M</given-names>
</name>
<name>
<surname>Moorlag</surname> <given-names>S</given-names>
</name>
<name>
<surname>Antonakos</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kotsaki</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dom&#xed;nguez&#x2013;Andr&#xe9;s</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Activate: Randomized Clinical Trial of BCG Vaccination Against Infection in the Elderly</article-title>. <source>Cell</source> (<year>2020</year>) <volume>183</volume>(<issue>2</issue>):<fpage>315</fpage>&#x2013;<lpage>23.e9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.051</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koeken</surname> <given-names>VACM</given-names>
</name>
<name>
<surname>De Bree</surname> <given-names>LCJ</given-names>
</name>
<name>
<surname>Mourits</surname> <given-names>VP</given-names>
</name>
<name>
<surname>Moorlag</surname> <given-names>SJCFM</given-names>
</name>
<name>
<surname>Walk</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cirovic</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>BCG Vaccination in Humans Inhibits Systemic Inflammation in a Sex&#x2013;Dependent Manner</article-title>. <source>J Clin Invest</source> (<year>2020</year>) <volume>130</volume>(<issue>10</issue>):<page-range>5591&#x2013;602</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI133935</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cirovic</surname> <given-names>B</given-names>
</name>
<name>
<surname>de Bree</surname> <given-names>LCJ</given-names>
</name>
<name>
<surname>Groh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Blok</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>J</given-names>
</name>
<name>
<surname>van der Velden</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment</article-title>. <source>Cell Host Microbe</source> (<year>2020</year>) <volume>28</volume>(<issue>2</issue>):<page-range>322&#x2013;34</page-range>. doi: <pub-id pub-id-type="doi">10.2139/ssrn.3376658</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saeed</surname> <given-names>S</given-names>
</name>
<name>
<surname>Quintin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kerstens</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Aghajanirefah</surname> <given-names>A</given-names>
</name>
<name>
<surname>Matarese</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Epigenetic Programming of Monocyte&#x2013;to&#x2013;Macrophage Differentiation and Trained Innate Immunity</article-title>. <source>Science</source> (<year>2014</year>) <volume>345</volume>(<issue>6204</issue>):<page-range>1578&#x2013;89</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.1251086</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Deutschman</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Seymour</surname> <given-names>CW</given-names>
</name>
<name>
<surname>Shankar&#x2013;Hari</surname> <given-names>M</given-names>
</name>
<name>
<surname>Annane</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bauer</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis&#x2013;3)</article-title>. <source>JAMA</source> (<year>2016</year>) <volume>315</volume>(<issue>8</issue>):<page-range>801&#x2013;10</page-range>. doi: <pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowman</surname> <given-names>DW</given-names>
</name>
<name>
<surname>Greene</surname> <given-names>RR</given-names>
</name>
<name>
<surname>Bearden</surname> <given-names>DW</given-names>
</name>
<name>
<surname>Kruppa</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Pottier</surname> <given-names>M</given-names>
</name>
<name>
<surname>Monteiro</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel Structural Features in Candida Albicans Hyphal Glucan Provide a Basis for Differential Innate Immune Recognition of Hyphae Versus Yeast</article-title>. <source>J Biol Chem</source> (<year>2014</year>) <volume>289</volume>(<issue>6</issue>):<page-range>3432&#x2013;43</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M113.529131</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pence</surname> <given-names>BD</given-names>
</name>
</person-group>. <article-title>Fanning the Flames of Inflammaging: Impact of Monocyte Metabolic Reprogramming</article-title>. <source>Immunometabolism</source> (<year>2020</year>) <volume>2</volume>(<issue>3</issue>):<fpage>e200025</fpage>. doi: <pub-id pub-id-type="doi">10.20900/immunometab20200025</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deleidi</surname> <given-names>M</given-names>
</name>
<name>
<surname>J&#xe4;ggle</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rubino</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Immune Ageing, Dysmetabolism and Inflammation in Neurological Diseases</article-title>. <source>Front Neurosci</source> (<year>2015</year>) <volume>9</volume>:<elocation-id>172</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2015.00172</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Neill</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Kishton</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Rathmell</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>A Guide to Immunometabolism for Immunologists</article-title>. <source>Nat Rev Immunol</source> (<year>2016</year>) <volume>16</volume>(<issue>9</issue>):<page-range>553&#x2013;65</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri.2016.70</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pence</surname> <given-names>BD</given-names>
</name>
<name>
<surname>Yarbro</surname> <given-names>JR</given-names>
</name>
</person-group>. <article-title>Aging Impairs Mitochondrial Respiratory Capacity in Classical Monocytes</article-title>. <source>Exp Gerontol</source> (<year>2018</year>) <volume>108</volume>:<page-range>112&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.exger.2018.04.008</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weyand</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Goronzy</surname> <given-names>JJ</given-names>
</name>
</person-group>. <article-title>Aging of the Immune System: Mechanisms and Therapeutic Targets</article-title>. <source>Ann Am Thorac Soc Dec: Am Thorac Soc</source> (<year>2016</year>) <issue>13</issue>(<supplement>Suppl 5</supplement>):<page-range>S422&#x2013;S8</page-range>. doi: <pub-id pub-id-type="doi">10.1513/AnnalsATS.201602-095AW</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ifrim</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Quintin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Joosten</surname> <given-names>LAB</given-names>
</name>
<name>
<surname>Jacobs</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jansen</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jacobs</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Trained Immunity or Tolerance: Opposing Functional Programs Induced in Human Monocytes After Engagement of Various Pattern Recognition Receptors</article-title>. <source>Clin Vaccine Immunol CVI</source> (<year>2014</year>) <volume>21</volume>(<issue>4</issue>):<page-range>534&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1128/CVI.00688-13</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Herre</surname> <given-names>J</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Willment</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Marshall</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Dectin&#x2013;1 Mediates the Biological Effects of Beta&#x2013;Glucans</article-title>. <source>J Exp Med</source> (<year>2003</year>) <volume>197</volume>(<issue>9</issue>):<page-range>1119&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20021890</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goodridge</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Wolf</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Underhill</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Beta&#x2013;Glucan Recognition by the Innate Immune System</article-title>. <source>Immunol Rev</source> (<year>2009</year>) <volume>230</volume>(<issue>1</issue>):<fpage>38</fpage>&#x2013;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00793.x</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McSai</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ruland</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tybulewicz</surname> <given-names>VLJ</given-names>
</name>
</person-group>. <article-title>The SYK Tyrosine Kinase: A Crucial Player in Diverse Biological Functions</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>10</volume>(<issue>6</issue>):<fpage>387</fpage>&#x2013;<lpage>402</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri2765</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metcalf</surname> <given-names>TU</given-names>
</name>
<name>
<surname>Cubas</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Ghneim</surname> <given-names>K</given-names>
</name>
<name>
<surname>Cartwright</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Grevenynghe</surname> <given-names>JV</given-names>
</name>
<name>
<surname>Richner</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Global Analyses Revealed Age&#x2013;Related Alterations in Innate Immune Responses After Stimulation of Pathogen Recognition Receptors</article-title>. <source>Aging Cell</source> (<year>2015</year>) <volume>14</volume>(<issue>3</issue>):<page-range>421&#x2013;32</page-range>. doi: <pub-id pub-id-type="doi">10.1111/acel.12320</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metcalf</surname> <given-names>TU</given-names>
</name>
<name>
<surname>Wilkinson</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Cameron</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Ghneim</surname> <given-names>K</given-names>
</name>
<name>
<surname>Chiang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wertheimer</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Human Monocyte Subsets Are Transcriptionally and Functionally Altered in Aging in Response to Pattern Recognition Receptor Agonists</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>199</volume>(<issue>4</issue>):<page-range>1405&#x2013;17</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1700148</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crooke</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Ovsyannikova</surname> <given-names>IG</given-names>
</name>
<name>
<surname>Poland</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Kennedy</surname> <given-names>RB</given-names>
</name>
</person-group>. <article-title>Immunosenescence and Human Vaccine Immune Responses</article-title>. <source>Immun Ageing</source> (<year>2019</year>) <volume>16</volume>(<issue>1</issue>):<fpage>25</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12979-019-0164-9</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seidler</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zimmermann</surname> <given-names>HW</given-names>
</name>
<name>
<surname>Bartneck</surname> <given-names>M</given-names>
</name>
<name>
<surname>Trautwein</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tacke</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Age&#x2013;Dependent Alterations of Monocyte Subsets and Monocyte&#x2013;Related Chemokine Pathways in Healthy Adults</article-title>. <source>BMC Immunol</source> (<year>2010</year>) <volume>11</volume>:<fpage>30</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2172-11-30</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stothers</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Burelbach</surname> <given-names>KR</given-names>
</name>
<name>
<surname>Owen</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Patil</surname> <given-names>NK</given-names>
</name>
<name>
<surname>McBride</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Bohannon</surname> <given-names>JK</given-names>
</name>
<etal/>
</person-group>. <article-title>&#x3b2;&#x2013;Glucan Induces Distinct and Protective Innate Immune Memory in Differentiated Macrophages</article-title>. <source>J Immunol</source> (<year>2021</year>) <volume>208</volume>(<issue>9</issue>):<fpage>ji2100107</fpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.2100107</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia&#x2013;Valtanen</surname> <given-names>P</given-names>
</name>
<name>
<surname>Guzman&#x2013;Genuino</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Hayball</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Diener</surname> <given-names>KR</given-names>
</name>
</person-group>. <article-title>Evaluation of Trained Immunity by Beta&#x2013;1, 3 (D)&#x2013;Glucan on Murine Monocytes <italic>In Vitro</italic> and Duration of Response <italic>In Vivo</italic>
</article-title>. <source>Immunol Cell Biol</source> (<year>2017</year>) <volume>95</volume>(<issue>7</issue>):<page-range>601&#x2013;10</page-range>. doi: <pub-id pub-id-type="doi">10.1038/icb.2017.13</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Safi</surname> <given-names>W</given-names>
</name>
<name>
<surname>Kuehnl</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nussler</surname> <given-names>A</given-names>
</name>
<name>
<surname>Eckstein</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Pelisek</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Differentiation of Human CD14+ Monocytes: An Experimental Investigation of the Optimal Culture Medium and Evidence of a Lack of Differentiation Along the Endothelial Line</article-title>. <source>Exp Mol Med</source> (<year>2016</year>) <volume>48</volume>(<issue>4</issue>):<fpage>e227</fpage>. doi: <pub-id pub-id-type="doi">10.1038/emm.2016.11</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonhardt</surname> <given-names>J</given-names>
</name>
<name>
<surname>Silke</surname> <given-names>G</given-names>
</name>
<name>
<surname>Christian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fatina</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sven</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tony</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Candida albicans &#x3b2;-Glucan Differentiates Human Monocytes Into a Specific Subset of Macrophages</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2818</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02818</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fullerton</surname> <given-names>JN</given-names>
</name>
<name>
<surname>Boelen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Rongvaux</surname> <given-names>A</given-names>
</name>
<name>
<surname>Maini</surname> <given-names>AA</given-names>
</name>
<etal/>
</person-group>. <article-title>The Fate and Lifespan of Human Monocyte Subsets in Steady State and Systemic Inflammation</article-title>. <source>J Exp Med</source> (<year>2017</year>) <volume>214</volume>(<issue>7</issue>):<page-range>1913&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20170355</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>